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Bradykinin Potentiation by Angiotensin-(1-7) and ACE
Inhibitors Correlates With ACE C- and N-Domain Blockade
Beril Tom, René de Vries, Pramod R. Saxena, A.H. Jan Danser
Abstract—ACE inhibitors block B2 receptor desensitization, thereby potentiating bradykinin beyond blocking its
hydrolysis. Angiotensin (Ang)-(1-7) also acts as an ACE inhibitor and, in addition, may stimulate bradykinin release via
angiotensin II type 2 receptors. In this study we compared the bradykinin-potentiating effects of Ang-(1-7), quinaprilat,
and captopril. Porcine coronary arteries, obtained from 32 pigs, were mounted in organ baths, preconstricted with
prostaglandin F2a, and exposed to quinaprilat, captopril, Ang-(1-7), and/or bradykinin. Bradykinin induced complete
relaxation (pEC5058.1160.07, mean6SEM), whereas quinaprilat, captopril, and Ang-(1-7) alone were without effect.
Quinaprilat shifted the bradykinin curve to the left in a biphasic manner: a 5-fold shift at concentrations that specifically
block the C-domain (0.1 to 1 nmol/L) and a 10-fold shift at concentrations that block both domains. Captopril and
Ang-(1-7) monophasically shifted the bradykinin curve to the left, by a factor of 10 and 5, respectively. A 5-fold shift
was also observed when Ang-(1-7) was combined with 0.1 nmol/L quinaprilat. Repeated exposure of porcine coronary
arteries to 0.1 mmol/L bradykinin induced B2 receptor desensitization. The addition of 10 mmol/L quinaprilat or
Ang-(1-7) to the bath, at a time when bradykinin alone was no longer able to induce relaxation, fully restored the
relaxant effects of bradykinin. Angiotensin II type 1 or 2 receptor blockade did not affect any of the observed effects
of Ang-(1-7). In conclusion, Ang-(1-7), like quinaprilat and captopril, potentiates bradykinin by acting as an ACE
inhibitor. Bradykinin potentiation is maximal when both the ACE C- and N-terminal domains are inhibited. The
inhibitory effects of Ang-(1-7) are limited to the ACE C-domain, raising the possibility that Ang-(1-7) synergistically
increases the blood pressure–lowering effects of N-domain–specific ACE inhibitors. (Hypertension. 2001;38:95-99.)
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Angiotensin (Ang)-(1-7) is a heptapeptide that is formedendogenously from both Ang I and Ang II.1 In rats and
dogs, Ang-(1-7) exerts direct vasodilatory effects via non–
angiotensin II type 1 (AT1), non–angiotensin II type 2 (AT2)
receptors, possibly by stimulating bradykinin and NO re-
lease.1,2 In contrast, in humans or pigs, no direct vasodilatory
effects of Ang-(1-7) were observed,3–7 although Ang-(1-7)
did antagonize the pressor effects of Ang II, suggesting that it
may cause vasodilation indirectly, by acting as an AT1
receptor antagonist.5,6 In addition, Ang-(1-7) potentiates bra-
dykinin, either via an AT2 receptor–dependent mechanism or
through inhibition of ACE.3,5,8 The latter effect is not neces-
sarily based on blockade of bradykinin hydrolysis, because
recent studies have shown that ACE inhibitors, including
Ang-(1-7), potentiate bradykinin by inhibiting desensitization
of its receptor.9–11 Somatic ACE has 2 homologous domains,
each containing an active center. According to their position
(N- or C-terminal), these domains are designated as the N- or
C-domain, respectively. Interestingly, Ang-(1-7) inhibits the
C-domain more potently than the N-domain (by 1 order of
magnitude)8 and is cleaved to Ang-(1-5) by the N-domain.12
In the present study, we investigated the bradykinin-
potentiating effects of Ang-(1-7) in porcine coronary arteries
(PCAs), its dependency on ACE, and the possible involve-
ment of AT1 and/or AT2 receptors. The effects of Ang-(1-7)
were compared with those of quinaprilat and captopril, 2
ACE inhibitors with preference for the ACE C-and
N-domains, respectively.13,14 We also verified the effect of
Ang-(1-7) in human coronary arteries (HCAs).
Methods
Tissue Collection
HCAs were obtained from 4 “heart beating” organ donors (2 men
and 2 women; age range, 14 to 38 years; mean6SEM age, 2365
years) who died of noncardiac causes (1 subarachnoid bleeding, 3
head trauma) ,24 hours before the heart was taken to the laboratory.
Hearts were provided by the Rotterdam Heart Valve Bank (Bio
Implant Services/Eurotransplant Foundation, Rotterdam, The Neth-
erlands) after removal of the aortic and pulmonary valves for
transplantation purposes. The study was approved by the joint ethics
committee of Erasmus University Rotterdam and University Hospi-
tal Rotterdam. Immediately after circulatory arrest, the hearts were
stored in an ice-cooled, sterile, organ-protecting solution. After
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arrival in the laboratory, the HCAs were removed and stored
overnight in a cold, oxygenated Krebs’ bicarbonate solution of the
following composition (mmol/L): NaCl 118, KCl 4.7, CaCl2 2.5,
MgSO4 1.2, KH2PO4 1.2, NaHCO3 25, and glucose 8.3 (pH 7.4).
Vessels were then cut into segments of ’4 mm in length, suspended
on stainless steel hooks in 15-mL organ baths containing Krebs’
bicarbonate solution, aerated with 95% O2/5% CO2, and maintained
at 37°C. Segments containing macroscopically visible atheroscle-
rotic lesions were not used.
PCAs were obtained from 32 pigs age 2 to 3 months
(Yorkshire3Landrace; weight, 10 to 15 kg). The pigs had been used
in in vivo experiments studying the effects of a-adrenoceptor and
serotonin receptor agonists and antagonists under pentobarbital (600
mg IV) anesthesia.15 The ethics committee of Erasmus University
Rotterdam dealing with the use of animals for scientific experiments
approved the protocol for this investigation. Hearts were explanted at
the end of the experiment, and the coronary arteries were removed
immediately and handled in the same way as HCAs.
Organ Bath Studies
All vessel segments were allowed to equilibrate for at least 30
minutes, and the organ bath fluid was refreshed every 15 minutes
during this period. Changes in tissue contractile force were recorded
with a Harvard isometric transducer. The vessel segments, stretched
to a stable force of ’15 mN, were exposed to 30 mmol/L K1 twice.
The functional integrity of the endothelium was verified by observ-
ing relaxation to 1 nmol/L substance P after preconstriction with 1
mmol/L prostaglandin F2a (PGF2a).16 Subsequently, the tissue was
exposed to 100 mmol/L K1 to determine the maximal contractile
response to K1. The segments were then allowed to equilibrate in
fresh organ bath fluid for 30 minutes. Thereafter, the following
experiments were performed.
First, Ang-(1-7) concentration-response curves (CRCs) (0.1
nmol/L to 10 mmol/L) were constructed in HCAs and PCAs, both at
baseline and after preconstriction with 10 mmol/L PGF2a, in the
absence or presence of the AT1 receptor antagonist irbesartan (1
mmol/L) or the AT2 receptor antagonist PD 123,319 (1 mmol/L).
Second, the effects of Ang-(1-7), quinaprilat, and captopril on
bradykinin-induced vasorelaxation were studied in PCAs. Vessels
were preincubated for 30 minutes in the absence or presence of
Ang-(1-7) (10 pmol/L to 10 mmol/L), quinaprilat (0.1 pmol/L to
0.1 mmol/L), captopril (0.1 pmol/L to 0.1 mmol/L), 10 mmol/L
Ang-(1-7)11 mmol/L irbesartan, 10 mmol/L Ang-(1-7)11 mmol/L
PD 123,319, 10 mmol/L Ang-(1-7)10.1 nmol/L quinaprilat, or 10
mmol/L Ang-(1-7)110 mmol/L quinaprilat. Vessels were then pre-
constricted with 10 mmol/L PGF2a or 1 mmol/L U46619, and CRCs
to bradykinin (0.1 nmol/L to 1 mmol/L) were constructed.
Third, the effect of quinaprilat and Ang-(1-7) on desensitized B2
receptors was studied in PCAs. Vessels were preincubated for 30
minutes with or without 1 mmol/L irbesartan or 1 mmol/L PD
123,319. Vessels were then preconstricted with 10 mmol/L PGF2a
and exposed 3 times to a concentration of bradykinin (0.1 mmol/L)
that is capable of inducing maximal relaxation. Each next exposure
was started as soon as the effect of the previous exposure had
disappeared, ie, after ’15 minutes. After the third exposure, when
bradykinin no longer exerted a vasodilatory effect, quinaprilat (10
mmol/L) or Ang-(1-7) (10 mmol/L) was added to the organ bath.
Thereafter, when the effects of quinaprilat and Ang-(1-7) had
disappeared, a fourth bradykinin dose (0.1 mmol/L) was added to the
organ bath.
Statistical Analysis
Data are given as mean6SEM and expressed as a percentage of the
contraction in response to PGF2a or U46619. CRCs were analyzed by
the logistic function described by de Lean et al17 to obtain pEC50
(210log EC50) values, EC50 representing the concentration at which
50% of the maximal relaxant effect has been reached. Statistical
analysis was by ANOVA, followed by post hoc evaluation (accord-
ing to Tukey or Dunnett where appropriate). Values of P,0.05 were
considered significant.
Results
Effect of Ang-(1-7) on HCAs and PCAs
Ang-(1-7), at concentrations up to 10 mmol/L, did not exert a
response in HCAs (n54) and PCAs (n55 to 12) at baseline
or after preconstriction with PGF2a or in the presence of
irbesartan or PD 123,319.
Effects of Ang-(1-7), Quinaprilat, and Captopril on
Bradykinin-Induced Relaxation in PCAs
Bradykinin caused complete relaxation of preconstricted
PCAs in a concentration dependent–manner (pEC5058.116
0.07; n512; Figure 1, top panel). Quinaprilat (10 mmol/L)
and captopril (10 mmol/L), like Ang-(1-7) at this concentra-
tion, did not exert any effect on preconstricted PCAs. How-
ever, in the presence of 10 mmol/L Ang-(1-7), the bradykinin
CRC was shifted ’5-fold to the left (pEC5058.7260.09;
n512; P,0.05 versus control), whereas in the presence of 10
mmol/L quinaprilat or 10 mmol/L captopril the bradykinin
CRC was shifted ’10-fold to the left (pEC5059.0360.21 and
8.9160.09, respectively; n58; P,0.01 versus control) (Fig-
ure 1, top panel). The effect of Ang-(1-7) on the bradykinin
CRC was not affected by irbesartan or PD 123,319 (Figure 1,
bottom panel).
To study the concentration dependency of the Ang-(1-7)–
and ACE-inhibitor–induced leftward shifts, bradykinin CRCs
Figure 1. Relaxations of PCAs, preconstricted with 10 mmol/L
PGF2a or 1 mmol/L U46619, to bradykinin in the absence (con-
trol) or presence of 10 mmol/L Ang-(1-7), 10 mmol/L quinaprilat,
or 10 mmol/L captopril (top). The effect of Ang-(1-7) on
bradykinin-induced relaxations was also studied in the presence
of 1 mmol/L irbesartan or 1 mmol/L PD 123,319 (bottom). Data
(mean6SEM of 5 to 12 experiments) are expressed as a per-
centage of the contraction induced by PGF2a or U46619. Ang-
(1-7), quinaprilat, and captopril significantly shifted the bradyki-
nin CRC to the left (P,0.05 vs control for Ang-(1-7); P,0.01 vs
control for the 2 ACE inhibitors), and the effect of Ang-(1-7) was
not influenced (P5NS) by the presence of irbesartan or PD
123,319.
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were also constructed in the presence of a wide range of
Ang-(1-7), quinaprilat, and captopril concentrations (Figure
2). The leftward shift caused by quinaprilat occurred in a
biphasic manner, with a 5-fold shift at concentrations in the
subnanomolar range and a 10-fold shift at concentrations .1
nmol/L. This biphasic shift is in agreement with earlier
studies13 demonstrating different quinaprilat binding affini-
ties of the ACE C- (Kd57 pmol/L) and N-domains (Kd51267
pmol/L) and suggests that the 5- and 10-fold shifts represent
C-domain inhibition and complete (ie, C- plus N-domain)
ACE inhibition, respectively. The 10-fold leftward shift
caused by captopril occurred monophasically (Figure 2),
suggesting that captopril is bound with similar affinity by the
2 ACE domains. The 5-fold leftward shift caused by Ang-
(1-7) also occurred monophasically (Figure 2), suggesting
either that Ang-(1-7) inhibits 1 ACE domain only or that
Ang-(1-7) potentiates bradykinin independently of its effects
on ACE. To sort out the latter, the effect of 10 mmol/L
Ang-(1-7) on top of quinaprilat, either at a concentration that
selectively inhibits the ACE C-domain (0.1 nmol/L) or at a
concentration that inhibits both ACE domains (10 mmol/L),
was studied. Ang-(1-7) affected neither the 5-fold leftward
shift of the bradykinin CRC at 0.1 nmol/L quinaprilat
(pEC5058.5960.39 and 8.6860.29 with and without Ang-
(1-7), respectively; n513; P5NS) nor the 10-fold shift at 10
mmol/L quinaprilat (pEC5059.0660.20 and 9.0360.21 with
and without Ang-(1-7), respectively; n511; P5NS) (Figure
3). Most likely, therefore, Ang-(1-7), at concentrations up to
10 mmol/L, acts as a selective inhibitor of the ACE
C-domain.
Effect of Ang-(1-7) and Quinaprilat on
Desensitized B2 Receptors in PCAs
Repeated exposure of preconstricted vessel segments to 0.1
mmol/L bradykinin produced progressively smaller responses
(Figure 4, top panel). The response to the third bradykinin
dose was ,50% of the response to the first bradykinin dose.
Quinaprilat or Ang-(1-7), added to the organ bath after the
effect of the third bradykinin dose had disappeared, both at a
concentration of 10 mmol/L, completely restored the relaxant
effect of bradykinin (90610% and 8368% relaxation, re-
spectively; n58; P5NS). A fourth bradykinin dose, added
after the effect of quinaprilat or Ang-(1-7) had disappeared,
induced no further effect. The effect of Ang-(1-7) was not
different in the presence of irbesartan or PD 123,319 (Figure
4, bottom panel).
Discussion
The present study shows that Ang-(1-7) potentiates the
vasodilator effects of bradykinin in PCAs through inhibition
of the ACE C-domain. AT1 or AT2 receptors are not involved
in this effect, nor did Ang-(1-7) exert direct (ie, indepen-
dently of bradykinin) relaxant effects in either HCAs or
PCAs. Furthermore, the maximal potentiating effect of Ang-
(1-7) was smaller than that of the ACE inhibitors quinaprilat
and captopril, suggesting that full potentiation will only be
obtained when both ACE domains are inhibited.
The concentrations of Ang-(1-7) required to obtain ACE
C-domain inhibition ($1 mmol/L) are in agreement with
previously reported values.5,8 These concentrations exceed
the in vivo tissue and plasma Ang-(1-7) concentrations in rats
and humans by at least 4 orders of magnitude. Ang-(1-7)
Figure 2. Change in 2log(EC50) of the bradykinin CRC in the
presence of increasing concentrations of quinaprilat (top), cap-
topril (middle), or Ang-(1-7) (bottom). An increase in 2log(EC50)
represents a leftward shift of the bradykinin CRC. Data
(mean6SEM of 6 to 8 experiments) were obtained in PCAs pre-
constricted with 1 mmol/L U46619. Con indicates control. Signif-
icant differences (P,0.05) vs control were obtained for quinapri-
lat, captopril, and Ang-(1-7) at concentrations $0.1, 100, and
1000 nmol/L, respectively.
Figure 3. Relaxations of PCAs, preconstricted with 10 mmol/L
PGF2a or 1 mmol/L U46619, to bradykinin in the absence (con-
trol, 1 symbols) or presence of 0.1 nmol/L quinaprilat (squares)
or 10 mmol/L quinaprilat (circles), with (closed symbols) or with-
out (open symbols) 10 mmol/L Ang-(1-7). Data (mean6SEM of
11 to 13 experiments) are expressed as a percentage of the
contraction induced by PGF2a or U46619. The addition of Ang-
(1-7) on top of quinaprilat did not have a significant effect.
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levels increase during ACE inhibition18–21 because ACE
inhibitors block the ACE N-domain–mediated degradation of
Ang-(1-7).1,8 However, the fact that most ACE inhibitors also
block the ACE C-domain will mask any potential C-domain–
blocking effect of the high Ang-(1-7) levels during ACE
inhibition. Indeed, Ang-(1-7) did not enhance bradykinin-
induced vasodilation in the forearm in human subjects treated
with an ACE inhibitor.7 Therefore, the effects of Ang-(1-7)
described in the present study may only be of physiological
importance if sufficiently high concentrations of Ang-(1-7)
are reached in the immediate vicinity of ACE (the levels
measured per gram tissue do not exclude this possibility)
and/or in combination with ACE inhibitors that specifically
block the ACE N-domain.
Studies with the N-domain–specific substrate N-acetyl-ser-
asp-lys-pro (AcSDKP) have revealed that the ACE inhibitor
captopril inhibits AcSDKP hydrolysis 16 times more potently
than Ang I hydrolysis.14 Because the ACE N- and C-domains
exhibit similar catalytic activities toward Ang I,22 these data
suggest that captopril, at low concentrations, preferentially
inhibits the ACE N-domain. Using captopril, however, we
were unable to make a clear distinction between the effects of
ACE N- and C-domain inhibition on the relaxant effects of
bradykinin. In contrast, using the ACE inhibitor quinaprilat,
which binds to the ACE C-domain with almost 200-fold
greater affinity than to the ACE N-domain,13 we could make
such a distinction: quinaprilat shifted the bradykinin CRC to
the left in a biphasic manner, with an ’5-fold shift occurring
at concentrations that selectively block the C-domain and an
’10-fold shift at concentrations that block both domains. Our
inability to find a similar biphasic shift in the presence of
increasing concentrations of captopril most likely relates to
the limited selectivity of this ACE inhibitor for the ACE
N-domain.
Ang-(1-7), like captopril, induced a monophasic leftward
shift of the bradykinin CRC. At the highest Ang-(1-7)
concentration (10 mmol/L) that was tested, however, the shift
was only half of that caused by similar concentrations of
quinaprilat or captopril. Adding quinaprilat, at a concentra-
tion that selectively blocks the ACE C-domain, to 10 mmol/L
Ang-(1-7) did not cause a further leftward shift, thereby
demonstrating that Ang-(1-7), at least at this concentration,
blocks the ACE C-domain only. Because a concentration of
10 mmol/L is already many orders of magnitude above the
measured concentrations of Ang-(1-7) in vivo,18–21 we did not
evaluate whether even higher concentrations of Ang-(1-7)
resulted in ACE N-domain inhibition.
Does ACE inhibition result in bradykinin potentiation by
blocking its hydrolysis? Because bradykinin, like Ang I, is
cleaved equally well by the 2 ACE domains,22 our finding
that blockade of both domains results in a twice as large
leftward shift as blockade of 1 domain appears to support this
possibility. However, the long half-life of bradykinin in this
preparation (30 minutes),3 as well as our previous finding in
PCAs that the quinaprilat-induced leftward shift of the
ACE-resistant bradykinin analogue [Hyp3-Tyr(Me)8]-
bradykinin was not different from that of bradykinin,11 argues
against this concept. Moreover, under conditions of B2
receptor desensitization (induced by repeated exposure to a
concentration of bradykinin that causes maximal relaxation),
when bradykinin itself was no longer active, both quinaprilat
and Ang-(1-7) immediately restored the effect of bradykinin.
Taken together, therefore, a more likely explanation for the
Ang-(1-7)–, quinaprilat-, and captopril-induced bradykinin
potentiation is the upregulation (or resensitization) of B2
receptors that has recently been described in Chinese hamster
ovary (CHO) cells transfected with the human B2 receptor
and human ACE.8,9,23,24 This effect only occurs when ACE
and B2 receptors are sterically closely associated, probably
forming a heterodimer.24 ACE inhibitors are believed to alter
the heterodimer interaction, thereby promoting a conforma-
tion in the B2 receptor that affects its sequestration and
coupling to second messengers.24 Our findings in intact PCAs
show that ACE-B2 receptor crosstalk is not limited to trans-
fected CHO cells and, in addition, suggest that the confor-
mational changes underlying bradykinin potentiation corre-
late directly with inhibition of the ACE C- and N-domains.
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